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COPY NUMBER VARIANT ANALYSIS OF PATIENTS WITH MALFORMATIONS 
OF CORTICAL DEVELOPMENT. 
Luis Kolb, Kaya Bilguvar, Michael Di Luna, Chris Mason, Yasar Bayri,  Ali Ozturk, 
Zulfikar Ayer, Nikhil Nayak, and Murat Gunel.  Department of Neurosurgery, Yale 
University School of Medicine, New Haven, CT. 
 
Copy Number Variants (CNVs) are DNA fragment that are approximately 1 kilobase (kb) 
to several megabases for which copy-number differences have been revealed by 
comparison of two or more genomes. The Human Genome project has led to the 
identification of close to 1500 of these variable regions covering 12% of the human 
genome. Even though many of these variants are considered to be benign, some of these 
genomic rearrangement have been found to be disease causing, including several nervous 
system disorders such as Charcot-Marie-Tooth, Williams-Beuren Syndrome, and Prader-
Willi syndrome. 
 
 In this study we have performed copy number variant analysis on 252 patients with 
cortical malformations. Cortical malformations represented in our cohort included 
patients with cortical dysplasia (95), lissencephaly (33), heterotopia (10), pachygyria (8), 
and polymicrogyria (20), among other diseases.   
 
 
Two disease-causing copy number variants were identified, and those two diseases are 
the focus of this manuscript: a diffuse villous hyperplasia of the choroid plexus, and 
cerebellar atrophy with pachygyria.  
 
Diffuse villous hyperplasia of the choroid plexus is a rare cause of hydrocephalus not 
amenable to shunting alone. Tetrasomy of the short arm of Chromosome 9 was identified 
using high-resolution genomic array mapping, broadening the phenotype of this 
described entity to include diffuse villous hyperplasia of the choroid plexus. 
 
Congenital ataxia with cerebellar hypoplasia is a heterogeneous group of disorders that 
presents with motor disability, hypotonia, incoordination, and impaired motor 
development. A homozygous deletion in the VLDLR gene was identified using high 
density single nucleotide polymorphism (SNP) micro arrays in a Turkish family with two 
siblings affected with cerebellar atrophy and pachygyria. Previous identification of 
VLDLR mutations in a Turkish family with quadrupedal gait led to various speculations 
ranging from “reverse evolution” to cultural influences. Discovery of disease causing 
homozygous deletions in a new Turkish family, which maintained bipedal movement, 
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Malformations of cortical development (MCD) are an important cause of epilepsy and 
developmental delay.1 It is estimated that up to 40% of children with refractory epilepsy 
have a cortical malformation.2 This group of disorders is composed of a large spectrum of 
abnormalities related to cortical development with varied genetic etiologies, anatomic 
abnormalities, and clinical manifestations. While prior to 1980 many of these disorders 
were solely diagnosed at autopsy, the use of magnetic resonance imaging (MRI) has 
dramatically improved our ability to recognize these diseases.  
 
Cerebral cortical development involves a series of highly organized and complex events, 
broadly including neural stem cell proliferation, migration, and neuronal differentiation. 
Disruptions of any of these various stages may result in malformations of cortical 
development. Disorders due to abnormalities of cell proliferation may cause 
microcephaly (small brain), megalencephaly (large brain), or cortical dysplasia (focal 
areas of abnormal neuronal architecture). Disorders of initiation of neuronal migration 
may result in periventricular heterotopia (PH) (abnormal nodules of neurons located 
along the ventricular wall). Disorders of later migration and motility cause disruption of 
the normal 6-layered cortex, such as classic lissencephaly (smooth brain) and subcortical 
band heterotopia (heterotopic neurons located midway between the surface of the brain 
and lateral ventricles). Finally, disorders of neuronal arrest can result in neurons that fail 
to stop upon reaching their intended destination in the cerebral cortex and over migrate 
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onto the cortical surface as is the case in cobblestone lissencephaly. Although cortical 
development has been separated into these stages, there is a significant overlap with no 
clear juncture, and many abnormalities may cause dysfunction at more than one level. 
Thus, malformation syndromes are typically classified based on the earliest assumed 
disruption of development. These concepts serve as the basis for the latest classification 
scheme for these disorders.3 (Table 1)  
 
 
The pathogenesis of these malformations is thought to be multifactorial. Genetic 
mutations or environmental insults, acquired either in utero at different stages of brain 
development or during the perinatal or postnatal period after corticogenesis, may all 
contribute to the development of these diseases. 4, 5  The extent of the malformation 
syndrome will be determined by the timing, severity, type of environmental influences, 






















Table 1: Classification of diseases of cortical development. 
 
 
I. Malformations due to abnormal neuronal and glial proliferation or 
apoptosis 
a. Decreased proliferation / increased apoptosis or increased proliferation / 
decreased apoptosis – abnormalities of brain size 
i. Microcephaly with normal to thin cortex 
ii. Microlissencephaly (extreme microcephaly with thick cortex) 
iii. Microcephaly with extensive polymicrogyria 
iv. Macrocephalies 
b. Abnormal proliferation (abnormal cell types) 
i. Nonneoplastic 
1. Cortical hamartomas of tuberous sclerosis 
2. Cortical dysplasia with balloon cells 
3. Hemimegalencephaly 
ii. Neoplastic (associated with disordered cortex) 
1. Dysembryoplastic neuroepithelial tumor 
2. Ganglioglioma 
3. Gangliocytoma 
II. Malformations due to abnormal neuronal migration 
a. Lissencephaly / subcortical band heterotopia spectrum 
b. Cobblestone complex / congenital muscular dystrophy syndromes 
c. Heterotopia 
i. Subependymal (periventricular) 
ii. Subcortical (other than band heterotopia) 
iii. Marginal glioneuronal 
III. Malformations due to abnormal cortical organization (including late 
neuronal migration) 
a. Polymicrogyria and schizencephaly 
i. Bilateral polymicrogyria syndromes 
ii. Schizencephaly (polymicrogyria with clefts) 
iii. Polymicrogyria or schizencephaly as part of multiple congenital 
anomaly / mental retardation syndromes 
b. Cortical dysplasia without balloon cells 
c. Microdysgenesis 
IV. Malformations of cortical development, not otherwise classified 
a. Malformations secondary to inborn errors of metabolism 
i. Mictochondrial and pyruvate metabolic disorders 
ii. Peroxisomal disorders 
b. Other unclassified malformations 
i. Sublobar dysplasia 
ii. Others 
 
Adapted from Barkovich et al. 3. 
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Work in determining the genetic basis of various MCD has given us greater insight and 
understanding into the underlying pathophysiology of these disorders. Different 
mutations of the same gene can cause different phenotypes, likely based on the degree of 
protein dysfunction (so termed genotype-phenotype correlation). Loss or disruption of the 
functional domains within a gene in some cases is enough to determine the phenotype of 
the disorder. Alternatively, specific mutations in a given gene can also lead to a gain of 
function for the aberrant protein. Mosaicism can occur when the mutation is present in a 
subpopulation of cells, whereas germ line mutations typically lead to expression of the 
mutant gene in all cells. Functional mosaicism occurs due to X-inactivation in which the 
mutation is present on 1 X chromosome but not the other. The mutant gene is then 
expressed only in cells in which the mutant gene is found on the active X chromosome, 
explaining why affected females often are less severely affected than males. An 
understanding of some of the underlying genetic basis for these disorders will play an 
important role in genetic counseling of affected individuals and their families.1 
 
Traditionally, genetic diseases are classified as chromosomal (numerical or structural); 
Mendelian (or single gene disorders); multifactorial/polygenic complex diseases; 
congenital anomalies; and diseases associated with specific mitochondrial gene 
mutations. Apart from chromosomal disorders, essentially all genetic disorders result 
from either some sort of alteration or mutation occurring in a specific gene (single gene 
diseases) or from the involvement of multiple loci spread across the human genome 
(polygenic disorders). Each of these disorders has major impact on patients. The majority 
of chromosomal disorders affect patients before birth and carry serious health burden 
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throughout childhood and during the early years of life. Single gene diseases peak around 
mid-childhood and pose a real medical and health burden from the perinatal period to 
adult age. In contrast polygenic/multifactorial disorders present late, with the exception 
of developmental anomalies requiring active multi-disciplinary care during the early life.6  
 
Genetic studies on human disease have been for long time limited to the investigation of 
single gene diseases.  These monogenic disorders tend to be rare, severe and follow clear 
patterns of inheritance that can be accurately traced through generations.  Once these 
diseases were adequately phenotyped, specific candidate genes within linkage intervals 
were searched for mutations in the patients and family members. More than 2000 
diseases have been identified in this manner, with most of these diseases caused by single 
base mutations that lead to missense or nonsense mutations according to the Database of 
Genomic Variants (http://projects.tcag.ca/variation/).  For example, four autosomal 
recessive genes are associated with microcephaly: Microcephalin7, ASPM (abnormal 
spindle-like, microcephaly-associated)8 9, CDK5RAP2 (CDK5 regulatory subunit-
associated protein 2) 10, and CENPJ (centromere protein J) 10. These genes seem to play a 
role in cell division during neurogenesis at the ventricular neuroepithelium by playing an 
important role in the regulation of microtubules and cell cycle progression during cell 
division.10 11-13 X-Linked mutations in FLNA 14-16and autosomal recessive mutations in 
ARFGEF2 (ADP-ribosylation factor guanine exchange factor 2) 17 are associated with 
Periventricular Heterotopia; and Subcortical band heterotopia is caused by mutations in 
the microtubule-associated DCX gene18. Several genes have been identified giving rise to 
classic lissencephaly: LIS1 (Lissencephaly1, autosomal dominant),19 DCX (Doublecortin, 
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X-linked dominant),20 TUBA1A (Tubulin alpha 1A, autosomal dominant),21, 22 ARX 
(Aristaless, X-linked dominant),23 and RELN (Reelin, autosomal recessive) 23, with 
causative genes having characteristic differences in the clinical and radiographic 
presentation. Cobblestone lissencephaly follows an autosomal recesive intheritance 
pattern and has been associated with POMT124, POMT225 , POMGnT126, and Fukutin27; 
genes involved in the glycosylation of α dystroglycan, a receptor for multiple 
extracellular molecules that maintains the stability of the cell surface.   Bilateral frontal 
and parietal polymicrogyria seem to be associated with mutations in the G-protein-
coupled receptor gene (GPR56)28, 29, assumed to play a role in the regional organization 












Table 2: Genetic basis of malformations of cortical development 
 
 
Syndrome Locus Gene Protein 
 
Autosomal recessive periventricular 
heterotopia / micrcocephaly 
 
8p23 MCPH1 Microcephalin 
 
Autosomal recessive periventricular 
heterotopia / micrcocephaly 
 
1q31 ASPM Abnormal spindle-like microcephaly 
 
Autosomal recessive microcephaly 
 
9q34 CDK5RAP2 CDK-5 regulatory-associated protein 2 
 
Autosomal recessive microcephaly 
 
13q12.2 CENPJ Centromere-associated protein J 
 
Autosomal recessive periventricular 
heterotopia / micrcocephaly 
 
20q13.13 ARFGEF2 ARFGEF2 
Amish lethal microcephaly 17q25.3 SLC25A19 Nuclear mitochondrial deoxynucleotide carrier 
Seckel syndrome 1 3q22-q24 ATR Ataxia telangiectasia and Rad3 related protein 
 
Isolated lissencephaly sequence 
 
Xq22.3-q23 DCX-XLIS DCX 
 
Subcortical band heterotopia 
 
Xq22.3-q23 DCX-XLIS DCX 
Miller-Dieker syndrome 17p13.3 Several contiguous 
PAFAH1B1, 14-3-3 and 
others 
 
Isolated lissencephaly sequence 
 
17p13.3 LIS1 PAFAH1B1 
 
Subcortical band heterotopia 
 
17p13.3 LIS1 PAFAH1B1 
 
Lissencephaly with cerebellar hypoplasia 
 
7q22 RELN Reelin 
 
X-linked lissencephaly with abnormal 
genitalia 
 
Xp22.13 ARX Aristaless-related homeobox protein 
 
Fukuyama congenital muscular 
dystrophy 
 
9q31 FCMD FCMD or Fukutin 
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Table 2: Genetic basis of malformations of cortical development (Cont.) 
 
 
Syndrome Locus Gene Protein 
 
Muscle-eye-brain disease 
 1p33-p34 POMGnT1 Unknown 
 
Muscle-eye-brain disease 
 19q13.3 FKRP Fukutin-related protein 
 
Congenital muscular dystrophy 19q13.3 FKRP Fukutin-related protein 
 
Congenital muscular dystrophy 









 19q13.3 FKRP Fukutin-related protein 
 
Walker-Warburg syndrome 
 9q31 FCMD FCMD 
 
Bilateral periventricular nodular 
heterotopia 
 Xq28 FLNA Filamin-A 
 
Bilateral periventricular nodular 
heterotopia + microcephaly 
 20q13.3 ARFGEF2 BIG2 
 
Bilateral periventricular nodular 
heterotopia 
 5p15 Unknown Unknown 
 
Tuberous sclerosis chromosome 1 
 9q32 TSC1 Hamartin 
 
Tuberous sclerosis chromosome 2 
 16p13.3 TSC2 Tuberin 
 
Bilateral frontoparietal polymicrogyria 
 16q13 GPR56 Unknown 
 
Warburg microsyndrome 1 
 2q21.3 RAB3GAP  
 
Bilateral perisylvian polymicrogyria 
 Xq28 Unknown Unknown 
 
Adapted from Barkovich et al. 3. 
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Recent advances in molecular genetics have enabled us to identify specific groups of 
disorders that result from previously uncharacterized mechanisms. Often these disorders 
do not conform to the standard basic principles of genetics, and involve specific areas of 
the human genome. A broad term ‘genomic disorders’ has been coined to describe these 
conditions6. Broadly, this group of disorders can be subdivided into disorders in the 
genome architecture, trinucleotide repeat disorders, chromosome breakage disorders, 
non-disjunction disorders, and complex genomic diseases. 6 
 
These disorders follow unusual non-traditional inheritance mechanisms that involve 
genomic regions that directly or indirectly influence the regulation and expression of one 
or more genes manifesting in complex phenotypes. The evolution of the mammalian 
genome has resulted in the duplication of genes, gene segments and repeats of gene 
clusters.30 This aspect of genome architecture provides recombination hot spots between 
non-homologous regions of chromosomes that are distributed across the whole genome. 
These genomic regions become susceptible to further DNA rearrangements that may be 
associated with abnormal phenotypes. 31-34 
 
These ‘hotspot’ regions usually lie within genomic regions referred to as Low Copy 
Number Repeats (LCR). LCR are region specific DNA blocks usually 10 to 300 
kilobases (kb) in size and of > 95% to 97% similarity to each other that usually map to 
two or three locations in the genome.35-37  It is estimated this regions account for ~5% of 
the human genome.  They can contain any standard constituent of genomic DNA, 
including gene families, gene containing structural motifs, or sequences of unknown 
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function present in clusters or dispersed through the genome. Examples include the HLA 
and related genes, actins, zinc-finger genes, and the CRI-S232 sequence family. LCRs are 
distinguished from highly repetitive sequences in the human genome by their high degree 
of sequence similarity and large numbers, and often appear to locate preferentially near 
centromeres and telomeres in human chromosomes.38, 39   
 
The term ‘genome architecture disorder’ refers to a disease that is a result of  an alteration 
of the genome that results in complete loss, gain or disruption of the structural integrity of 
dosage sensitive genes.40, 41 Disruption in the function of dosage sensitive gene may 
result from number of mechanisms including gene interruption, gene fusion, position 
effect, unmasking of a recessive allele, presence of a functional polymorphism, and gene 
transvection effect.6 Notable examples include a number of microdeletion / 
microduplication syndromes such as Williams- Beuren syndrome 42, Prader-Willi 
syndrome43, Angelman syndrome44, Smith Magenis syndrome45, Potoki Lupski 
syndrome45, DiGeorge syndrome46, and Neurofibromatosis type 147. (Table 3)  In these 
conditions there is a critical rearranged genomic segment flanked by large (usually > 10 
kb), highly homologous low copy repeat structures that can act as recombination 
substrates.48 Meiotic recombination between non-allelic LCR copies, also known as non-
allelic homologous recombination, can result in deletion or duplication of the intervening 
segment6. The phenotype of these disorders is distinctly recognizable with particular 
clinical and facial dimorphic features.  
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An increasing number of Mendelian diseases are being recognized to result from 
recurrent inter and intra chromosomal rearrangements involving unstable genomic 
regions.6 These genomic regions have been shown to be predisposed to non-allelic 
homologous recombination by proximity to ‘hot spot’ genomic segments.49  Large 
genomic deletions and duplications have been reported as being pathogenic in cases of 
various diseases, such as Duchenne and Becker muscular dystrophies, familial breast 
cancer, hereditary nonpolyposis colorectal cancer, and Williams-Beuren syndrome. 
(Table 4) Previously, our lab reported a homozygous microdeletion in the parkin gene 
(PARK 2) in a Turkish family in which six members were afflicted with autosomal 
recessive Parkinsonism. 50 Mutations in the PARK2 gene had been previously shown to 
be associated with early-onset Parkinson’s disease51. 
 
Even though traditionally when one considers what constitute ‘genetic diseases’ one 
usually refers to traits inherited in a Mendelian fashion and resulting from base pair 
changes that alter an encoded protein’s structure, function and regulation, clinical 
conditions observed in genetics are sporadic in >97% of the cases.  Often these cases are 
not due to mutant genes, but instead result from genomic copy number variations.52 2-3% 
of children are born with a major birth defect and often these are sporadic in nature.53, 54  
Chromosomal anomalies, such as trisomy 21, have been shown to be responsible for birth 
defects in ~0.2% of live births.55 Recessive traits are thought to compose a similar 
proportion .55  De novo point mutations are also known to cause sporadic disease as is in 
common cases of achondroplasia, neurofibromatosis type 1, and tuberous sclerosis, as 
well as multiple other diseases.52    
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Direct estimates of human per-nucleotide rates for spontaneous mutations have been 
estimated to between 0.5 x 10-8 to 3 x 10-8  from the per-locus mutation rates and 
sequences of de novo nonsense nucleotide substitutions, deletions, insertions, and 
complex events causing autosomal dominant and X-Linked diseases56.  In the context of 
the 3 x109 bp haploid human genome, this rate corresponds to ~60 new mutations per 
germ cell, with male germ cells having more than female germ cells as most point 
mutations presumably represent DNA replication or repair errors.  Approximately 2% 
(2.4) of them will affect exonic sequences, thus about two exons (and thus genes) have a 
de novo base-pair change. Of these, at least one third are likely to have little effect as 
they would lie in the third position of a codon.52 Thus, it seems paternal age affect is the 
most likely cause of ‘sporadic cases’ often being found among the last-born children of a 
sibship.57, 58  
 
In contrast, the de novo locus-specific mutation rates for genomic rearrangements has 
been calculated to be between 10-6 and 10-4 from sporadic microdeletion syndromes, 
common autosomal dominant or X-Linked disease prevalence rates, by direct 
measurement by either sperm PCR at the alpha globin or t(11;22) recombination 
breakpoint sites, and by genomic assays comparing child to parents in trios.52 This rate is 
at between 2 and 4 orders of magnitude (100 to 100,000 fold) greater than observed rates 
of de novo locus-specific mutation point mutations. It appears that genomic 
rearrangements are more common than point mutations, and that the mechanisms causing 
them are more prevalent as well. 
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There appears to be three primary recombination mechanisms responsible for generating 
deletions and duplications that cause genomic rearrangements that can be associated with 
genomic disorders.49 Nonallelic homologous recombination (NAHR), described above, 
appears to be the more frequent mechanism for specific regions of the genome that have 
architecture that favors genomic instability, and has been proposed as the main 
mechanism for genomic rearrangements due to the proximity of most genomic 
rearrangements to low copy repeats40, 59. This seems to be especially true for most of the 
recurrent rearrangements that share a common size, show clustering of breakpoints, and 
recur in multiple individuals. In this process, non-allelic copies of LCRs, instead of the 
copies at the usual allelic positions, are aligned in meiosis or mitosis. This 
‘misalignment’ results in genomic rearrangements in the progeny cells. When the two 
LCRs are located on the same chromosome and in direct orientation, the resulting 
rearrangement is either a deletion or duplication. When the LCRs are in the same 
chromosome but in opposite orientation, the process results in inversion of the fragment 
flanked by them. Non-allelic homologous recombination on different chromosome results 
in chromosomal translocation.41  
 
Nonhomologous end joining (NHEJ) and the Fork Stalling and Template Switching 
(FoSTeS) have been proposed as the other two mechanisms responsible for genomic 
rearrangements, especially for the non-recurrent cases.  Non-recurrent rearrangements are 
of different sizes in each patient, but may share a small region of overlap whose change 
in copy number may result in shared clinical features among different patients.59 These 
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non- recurrent rearrangements might be stimulated by low copy repeat regions, as well as 
might be mediated by highly homologous repetitive sequences such as the Alu, and LINE 
sequences.  
 
Nonhomologous end joining (NHEJ), which plays a critical role in V D J recombination -
the process by which B-cell and T-cell diversity is generated, is one of the two major 
mechanisms used by eukaryotic cells to repair both physiological and pathological double 
stranded breaks (DSB).60, 61  NHEJ is considered to be the major mechanism responsible 
for joining translocated chromosomes in cancer.61 The process proceeds in four steps: 
detection of DSB; molecular bridging of both broken DNA ends; modification of the 
ends; and ligation of the ends.  Sequence studies on non-recurrent deletions in the DMD 
gene and the PLP1 gene, as well as duplications on the PLP1 have found evidence these 
genomic rearrangements are caused by the NHEJ mechanism.62, 63 It has been proposed 
that the first step of the rearrangement is when a single DSB occurs in one strand; 
followed by the broken ends being invaded and copied from the sister chromatid; and 
finally the ends being rejoined via NEHJ. 
 
Some rearrangements are far more complex than those able to be explained by NAHR 
and NEHJ mechanisms. To explain these more complex events, the Fork Stalling and 
Template (FoSTees) model has been proposed.64 In this model, during DNA replication 
the DNA replication fork stalls at one position causing the lagging strand to disengage 
from the original template, and transfer and anneal to another replication fork in physical 
proximity. The DNA replication process then ‘primes’ again, and continues DNA 
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synthesis65. Switching to another folk located downstream would result in a deletion, 
while switching to a fork upstream would result in duplication. The process of 
disengaging, invading/annealing, synthesis/extension could occur multiple times resulting 
the observed complex rearrangements.49  Although still very limited, preliminary data 
implies that FoSTeS might be a major mechanism of duplication, and might have also 
been the driving force in the origin of Low Copy Repeats. 
 
Eighteen years ago it became evident that genomic rearrangements and gene dosage 
effects, rather than the classical model of coding region DNA sequence mutations, could 
be responsible for nervous system diseases when a duplication in CMT1A was 
discovered to be responsible for Charcot-Marie Tooth neuropathy type 1a, a common, 
autosomal dominant adult-onset neurodegerative disease.66, 67  Now, several 
neurodegenerative and neurodevelopmental disorders are known to be caused by 
disparate recurrent and non-recurrent genomic rearrangements.68 These genomic 
disorders include peripheral and central nervous system neuropathies, well-recognized 
syndromes with characteristic phenotypes, and also a growing group of psychiatric 
illnesses.  Some of these disorders include the deletion in PMP22 causing hereditary 
neuropathy with liability to pressure palsies (HNPP), and some of the recurrent 
microdeletion disorders previous mentioned like Williams-Beuren Syndrome42, 




Several new genomic disorders caused by genomic rearrangements leading to nervous 
system diseases have been recently recognized. Duplications of the genomic region 
deleted in Williams-Beuren syndrome have been described, with patients characterized 
by prominent speech delay.42, 69, 70 Tandem duplications of LMNB1 have been reported to 
cause adult-onset autosomal dominant leukodystrophy71, and duplications in 
PAFAH1B1/LIS1 and YWHAE –genes deleted in lissencephaly (PAFAH1B1/LIS1 alone) 
and Miller-Dieker syndrome (both) were found in patients with developmental delay72, 73. 
Finally, two new microdeletion syndromes have been described in 17q21.3174, 75 and 
15q13.376, and the reciprocal duplications, have been recognized.  
 
With the advent of the completion of the Human Genome, thousands of single nucleotide 
polymoprhisms have been discovered and their use as common polymorphic markers has 
revolutionized genome-wide studies. A SNP is a variation of a single nucleotide in the 
DNA sequence that occurs between members of the same species. SNPs may fall within 
the coding sequence of genes, intronic sequence of genes, or in intergenic regions.  Some 
SNPs may contribute directly to disease phenotype by altering the gene function, 
especially those lying within the coding sequences. The majority, though, are located 
outside protein coding regions.77  
 
There are approximately 10 million SNPs with a minimum allele frequency of 1% that 
have been discovered spread throughout the genome.78 A minimum allele frequency of 
1%, which means the rarer allele occurs with a frequency of at least 1% of the population, 
is commonly used as a cutoff when considering a single base change as a rare variant or 
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polymorphisms.  Assays have been developed using SNPs as markers that are cheap and 
easy to perform and take advantage of SNPs being numerous, frequent and stable.  These 
assays are increasingly being used in genome wide studies of individuals, families and 
populations. 
 
A large, well-characterized collection of SNPs has become increasingly important in the 
discovery of DNA sequence variations that affect biological function.  A block of 
associated SNPs in a region of the genome is called a haplotype. Many parts of the 
genome exist with distinctive areas of common haplotypes, which account for most of the 
individual variation within a population. The International HapMap Project is an 
international collaboration with the goal of developing a haplotype map of the human 
genome, which will describe the common patterns of human genetic variation.79 In many 
ways this is information is thought to simplify the human genome so that instead of 
having to scan through 10 million SNPs to explain human variation, it may be possible to 
breakdown the genome into specific areas of increase variation that can be specifically 
tagged with SNPs, thereby reducing the amount of genotyping required. The current 




In addition to the identification of thousands of SNPs, the Human Genome project has led 
to the identification of a range of other DNA sequence variations such as insertions, 
deletions, and translocations of various segments of chromosomes.81  The term Copy 
Number Variant (CNV) was coined to describe a copy number change involving a DNA 
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fragment that is approximately 1 kilobase (kb) to several megabases for which copy-
number differences have been revealed by comparison of two or more genomes. These 
changes can be copy-number gains (duplications or insertional transpositions, losses 
(deletions), gains or losses of the same locus, or multiallelic or complex rearrangements. 
This excludes insertions or deletions involving transposable elements.  Even though it 
was well known previous to the Human Genome Project that large duplications and 
deletions have a mechanistic role in the development of a range of human genetic 
diseases, it was during the Human Genome Project and subsequent studies that it was 
appreciated that humans carry a far higher than expected number of CNVs.82-84 It has 
been speculated there are close to 1500 variable regions covering 12% of the human 
genome that equal or even surpass the number of nucleotides affected by SNPs. 85  
  
CNV discovery will continue. Many of these CNVs are likely to represent benign 
variants, but proving they do not have phenotypic consequences or that they do not 
account for normal physical or behavioral traits will be a challenge. It is also a challenge 
to establish a cause-and-effect relationship for a specific genomic rearrangement and a 
given phenotype; and even more of a challenge to determine the dosage-sensitive gene or 
genes within the genomic rearrangement. Regardless, when analyzing genetic disorders, 
one should consider new mutation. Given that the frequency of de novo structural 
changes can be four orders of magnitude greater than that of base pair changes, CNV 
should be considered a potential significant cause of sporadic disease and Mendelian 
disorders. These diseases include the malformations of cortical development detailed 
above. 
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STATEMENT OF PURPOSE & SPECIFIC AIMS 
 
The purpose of this study is to utilize molecular genetics techniques, specifically SNP 
genotyping, CNV analysis and homozygosity mapping, in order to find genetic mutations 
that cause diseases of neural development.  This manuscript details our studies on our 
neurogenetics cohort and on two diseases in particular:  Cerebellar Atrophy, and Choroid 
Hyperplasia.  Our aim is to uncover the gene mutations that cause these disorders so that 
we may develop a better understanding of the pathophysiology of these diseases 








Patient Identification and Collection of Blood Samples 
 
Approval for this study was obtained from the Yale Human Investigations Committee 
(Protocol 7680).  The patients afflicted with malformations of cortical development were 
identified by physicians at Yale New Haven Hospital as well as collaborators at other 
institutions in the United States and Europe. Diagnosis for each patient was established 
by the identifying physician based on physical findings, computerized tomography (CT) 
findings, and/ or magnet resonance imaging (MRI) findings. For patients identified at 
Yale New Haven Hospital, the author attained consent and collected their blood samples.  
For patient identified elsewhere, consent was attained and blood samples were collected 
by the collaborating physicians, and Ethical Committee approval was obtained from each 
institution.   
 
 
Isolation of Genomic DNA 
 
Total genomic DNA was isolated from lymphocyte nuclei using a procedure described by 
Bell et al. 86.  Ten milliliters of blood collected in a heparinized tube and then kept at 4°C 
was mixed with 90 ml of 0.32 M sucrose / 10 mM TrisHCl (pH 7.5) / 5 mM MgCl2 / 1% 
Triton X-100 at 4°C to lyse all cells.  The nuclei were collected by centrifugation at 1000 
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X g for 10 min.  The nuclear pellet was suspended in 4.5 ml of 0.075 M NaCl / 0.024 M 
EDTA (pH 8.0) with a Pasteur pipette.  Then 0.5 ml of 5% sodium dodecyl sulfate and 
proteinase K at 2 mg/ml were added and the mixture was incubated for approximately 12 
hr at 37°C.   
 
The digest was gently mixed with 5 ml of phenol saturated with 20 mM Tris HCl (pH 
8.0).  Five milliliters of chloroform / isoamyl alcohol (24:1, vol/vol) was added and 
gentle mixing was continued.  The phases were separated by centrifugation for 15 min at 
1000 X g.  The upper, aqueous, phase was removed and gently extracted with the 
chloroform / isoamyl alcohol mixture.  After centrifugation, the aqueous phase was 
removed; 0.5 ml of 3 M sodium acetate and 11 ml of 100% ethanol (at room temperature) 
were added.  The DNA was precipitated by inverting the tube several times and then 
removed with a Pasteur pipette and placed in 1 ml of 10 mM Tris HCl (pH 7.5) / 1 mM 
EDTA.  The DNA was allowed to dissolve at 4°C.  From 10 ml of blood, 20-50 µg of 
DNA was obtained.  In cases where the yield is low, we incubate the DNA at -20°C in 
the presence of ammonium acetate. Genomic DNA was isolated by the author and 
laboratory technicians.     
 
 
Single Nucleotide Polymorphism Genotyping and Quality Control 
 
Single Nucleotide polymorphism genome-wide genotyping was performed on the 
Illumina plataform 370 Human CNV and the Human610-Quad Beadchip (containing 
 22 
379.473 and 620,089 SNPs respectively; Illumina, San Diego, CA, USA). All procedures 
were done according to manufacturer’s protocol.  Briefly, 200 ng of genomic DNA was 
amplified, fragmented, and hybridized to the array, and products were fluorescently 
labeled and scanned with Illumina Beadstation scanner. Raw data was then uploaded in 
Beadstudio v3.3 genotyping software (Illumina, San Diego, CA, USA) for further 
analysis.  Samples  of  subjects  that  had  genotype  call  rates  <  97%  (n=6), 
 heterozygosity  >  37%  (n=3)  or  samples  with  incorrectly  imputed  gender  (n=0) 





Data was analyzed using BeadStudio v3.3 (Illumina Inc., San Diego, CA). Two metrics 
were visualized using this tool: B allele frequency and log R ratio. The B allele frequency 
is the theta value for an individual SNP corrected for cluster position. This parameter 
provides an estimate of the proportion of times an individual allele at each polymorphism 
was called A or B. In this setting, an individual who is homozygous for the B allele (BB 
genotype) would have a score close to 1, an individual homozygous for the A allele (AA) 
would have a score close to 0, and an individual who is heterozygous (AB) would have a 
score of approximately 0.5. Significant deviations from these figures in contiguous SNPs 
are indicative of a CNV. The log R ratio is defined as the log (base 2) ratio of the 
observed normalized R value for the SNP divided by the expected normalized R value for 
the SNPs theta value. The expected R value is calculated from the values theta and R, 
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where R is the intensity of dye labeled molecules that have hybridized to the beads on the 
array and theta is the ratio of signal at each polymorphism for beads recognizing an A 
allele to beads recognizing a B allele. The expected R value for any individual at any 
typed SNP is calculated using a large population of typed individuals. Therefore, the ratio 
of observed R to expected R in any individual at any SNP gives an indirect measure of 
genomic copy number. An R value above 1 is indicative of an increase in copy number, 
and an R value below 1 suggests a decrease (deletion) in copy number. While this metric 
exhibits a high level of variance for individual SNPs, it does provide a measure of copy 
number when log R ratio values for numerous contiguous SNPs are visualized.  We 
evaluated both the log R ratio and the B allele frequency plots across the genome in all 




















Figure 1: Homozygous Deletion example. Log R ratio plot. Scatter points represent 
normalized log2 ratios (y) for probes along the chromosome. A segment was considered 
to be significant if y > 3 or y < -3. A deletion spanning 2 consecutive probes with y < -3 















 Figure 2: Heterozygous deletion example. Log R ratio plot. Scatter points represent 
normalized log2 ratios (y) for probes along the chromosome. A segment was considered 







A previously described high-resolution CNV detection algorithm, the PennCNV 
algorithm 87, was used to infer CNVs from the signal intensity data. This algorithm 
incorporates multiple sources of information, including total signal intensity and allelic 
intensity ratio at each SNP marker, the distance between neighboring SNPs, the allele 
frequency of SNPs, as well as family information when available. We set a threshold at 2 
SNPs for homozygous deletions and 10 SNPs for heterozygous deletions to avoid false 
positive calls. This threshold was previously shown to result in a false positive rate lower 
than 1% for high-quality samples 87, 88. 
To define common and rare CNVs we mapped these CNVs to the UCSC genome browser 
for comparison with those previously identified in other publications, or with those 
included in the database of genomic variants (http://projects.tcag.ca/variation). The 
common and rare CNVs were defined as those that occurred at a frequency of >1% or 
<1% in general populations. The CNVs which were not detected in control subjects and 
in the database of genomic variants were considered to be possibly disease causing. 




Plink software, a whole genome association analysis toolset, was used to calculate the 
inbreeding coefficient for each individual patient using the B allele signal data.89  The 
Inbreeding coefficient is a measure of how close two people are genetically to each other. 
Plink calculates the inbreeding coefficient based on the observed versus expected number 
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of homozygous genotypes given a large number of SNPs in a homogeneous sample. 
Inbreeding coefficient calculations were performed by the author and laboratory 




Plink software was used to conduct runs of homozygosity for each individual patient 
using the B allele signal data.89 In brief, the Plink algorithm performs a run of 
homozygosity by taking a window of X SNPs and sliding this across the genome. At each 
window position it determines whether this window looks 'homozygous' enough (yes/no) 
(i.e. allowing for some number of heterozygous or missing calls). Then, for each SNP, it 
calculates the proportion of 'homozygous' windows that overlap at that position.  It 
creates a call for segments based on this metric, e.g. based on a threshold for the average. 
Homozygous runs were performed using the 100 SNP, 1000 kb windows with SNP 
densities of 1 SNP per 50 kilobases. One heterozygous SNP call and 5 missing SNP calls 
were allowed per homozygous window.  Homozygosity runs were performed by the 





Candidate Gene Mutational Analysis 
 
Exon-intron boundaries of the candidate genes were determined based on the University 
of California at Santa Cruz (UCSC) Genome Browser (NCBI Build 36.1).  PCR primers 
were designed using PRIMER3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). .  The Basic Local Alignment Search Tool 
(http://www.ncbi.nlm.nih.gov/blast/) was used for these primers. Exon amplicons were 
amplified and sequenced using standard techniques.  Mutational analysis was performed 





Array CNV analysis results were confirmed with quantitative RT-PCR using the standard 
curve method for absolute quantization.  Primers were designed using Primer Express 
Software, version 2.0 (Applied Biosystems), with the following criteria: amplicon size of 
80 to 200/250 bp, GC content of 20 to 80%, no more than two guanines or cytosines in 
the primer 3’ end, and melting temperature (Tm) of 59 to 60°C.  Finally, the Basic Local 
Alignment Search Tool (http://www.ncbi.nlm.nih.gov/blast/) was used for these primers. 
 
The experimental design and calculations were performed as described by Applied 
Biosystems (User Bulletin #2).  To determine copy number changes, fourfold ranges of 
five different serial dilutions from five pooled normal control DNA samples were used.  
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In addition, we used 5 ng of genomic DNA from the patient’s DNA and pooled normal 
control DNA.  The RT-PCRs were performed in triplicate for each reaction.  The 15-µl 
reactions contained 1X final concentration of Power SYBR Green PCR Master Mix (part 
number 4367660, Applied Biosystems) and 400 nM of each primer (Invitrogen).  Each 
experiment was performed using a 384-well optical PCR plate and the Applied 
Biosystems machine (model 7900HT) with default cycling conditions. 
 
A standard curve was created using the calculated threshold cycle of each dilution for 
each gene.  Amplifications were performed on the same diluted samples using primers for 
the reference and target genes.  For all experimental samples, the target quantity was 
determined from the standard curve and divided by the target quantity of the normal 
reference DNA.  To assess reaction specificity and to verify product identity, melting 
curve analysis was performed following amplification.  We used the standard curves with 
an efficiency between 90% and 100%, which corresponds to a slope between 23.58 and 






To this date, 563 patients with malformations of cortical development and 
syndromic neurodevelopment diseases have been collected from Yale-New Haven 
Hospital as well as from collaborators in Europe. Of these 563 patients, 252 patients were 
diagnosed with cortical malformations and were included in this study. Patients within 
the designation of cortical malformations included patients diagnosed with 
polymicrogyria (20), schizencephaly (16), developmental anomaly/ dysplasia (39), and 
broadly as malformations of cortical development not specified (MCD - 95). 130 patients 
were genotyped on 370k microarray Illumina Human CNV bead chips, while 119 
patients were genotyped on the Illumina 610 Quad chips. Beadchip data from six (6) 
chips with call rates less than 97% was considered to be of poor quality and was excluded 
from this study. Genotype analysis also revealed three duplicates, which were removed as 
well. Sex phenotype on the bead chip data for each patient was also cross-matched with 
the reported sex to validate the integrity of the each patient sample. 
A control group composed of forty (40) patients with a diagnosis of renal tubular 
acidosis and of self-reported consanguinity was also genotyped on 370k Human CNV 












Figure 3: Demographics of Neurogenetics cohort. Total number of patients 















Figure 4: Demographics of patients with cortical malformations within the 
Neurogenetics Cohort.  Total number of patients with cortical malformations is 








Copy Number Variant Analysis 
 
Analysis for copy number variants was performed using the Penn CNV algorithm in 
conjunction with visual inspection of the signal intensities on the Beadstudio plataform. 
Because of the difference in SNP densities between the two microarray platforms, results 
are presented divided.  
 
 
Copy Number Variant Analysis of patients on Illumina 370 Human CNV (N=127) 
 
Copy number variant analysis of the 127 patients genotyped on the Illumina 370 Human 
CNV bead chips revealed 20 homozygous deletions and 237 heterozygous deletions. Of 
the 20 homozygous deletions, 7 contain or are within genes. Comparing these seven copy 
number variants with the published reports and database of human variation eliminates 
six areas where there is evidence of variability in the general population. One intergenic 
deletion has not previously been reported.  
 
 
Copy Number Variant Analysis of patients on Illumina 610 Quad (N=119) 
 
Copy number variant analysis of the 119 patients genotyped on the Illumina 610 Quad 
Chips revealed 593 homozygous deletions and 840 heterozygous deletions. Of the 593 
homozygous deletions, 130 contain or are within genes. Comparing these 130 copy 
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number variants with the published reports and database of human variation eliminates 
128 areas where there is evidence of variability in the general population. Two exonic 
homozygous deletions are not previously reported, and are located in the VLDLR gene 
(see below). 
 
Copy Number Variants on Illumina 370 Human CNV 
 






CORTICAL DYSPLASIA 5 1 4 0 
DEVELOPMENTAL ANOMALY 37 6 35 0 
DNET 9 2 6 0 
HETEROTOPIA 6 0 5 0 
LISSENCEPHALY 22 2 37 0 
MCD 20 5 29 1 
MULTIPLE 3 2 58 0 
POLYMICROGYRIA 17 1 35 0 
SCHIZENCEPHALY 8 1 28 0 
Total 127 20 237 0 
 
Table 5: Genomic Deletions per Malformations of Cortical Development Sub-group in patients 






Copy Number Variants on Illumina 610 Quad 
 






CORTICAL DYSPLASIA 7 25 35 0 
PACHYGYRIA 8 35 58 2 
DNET 1 6 4 0 
HETEROTOPIA 4 23 25 0 
LISSENCEPHALY 8 33 94 0 
MCD 74 395 500 1 
MULTIPLE 6 24 47 0 
POLYMICROGYRIA 2 13 15 0 
SCHIZENCEPHALY 8 39 62 0 
Total 119 593 840 0 
 
Table 6: Genomic Deletions per Malformations of Cortical Development Sub-group in patients 





Copy Number Variant Analysis of Controls 
 
Copy number variant analysis of the 40 controls on the Illumina 370 Bead chips revealed 
fifteen homozygous deletions and 139 heterozygous deletions. Of the fifteen homozygous 
deletions, seven are within genes. Comparing these 7 copy number variants with the 
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published reports and database of human variation eliminates one area of common 
variability. Five homozygous mutations are known to cause autosomal recessive cases of 






Figure 5: Homozygous deletions within genes in the control population (N = 40). 
Mutations in CLCNKA and CLCNKB, part of the family of voltage-gated chloride 
channels, have been associated with Barter’s syndrome Type 4, an autosomal recessive 
disorder defined by hypokalemic metabolic acidosis (OMIM # 602522). Mutations in 
FRAS1, which encodes a putative extracellular matrix (ECM) protein, is mutated in 
Fraser syndrome (OMIM #219000). 
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Copy Number Variant Analysis of Heterozygous Deletions and Amplifications 
 
We are currently in the process of further investigating identified heterozygous deletions 
as well as amplifications on our samples (results not shown) in order to identify 








Diffuse villous hyperplasia of the choroid plexus (DVHCP) is defined as diffuse 
enlargement of the entire choroid plexus occurring throughout the length of the choroid 
fissure.  DVHCP is a rare cause of hydrocephalus which according to contemporary case 
reports, is not adequately treated by shunting; It is a rare disorder, having been reported 
in only a handful of cases90-94.  Hydrocephalus and congenital malformations of the 
Dandy-Walker Complex are not often associated with chromosomal abnormalities.  
Herein we describe a case of a female child born with hydrocephalus, and multiple 
craniofacial anomalies including cleft palate and lip.  CT scan demonstrated DVHCP and 







Figure 6:  Axial non-contrast head CT. Representative images through the lateral 
ventricles (A) and third ventricle (B) demonstrate hydrocephalus, diffuse enlargement of 
the arachnoid spaces, diffuse villous hyperplasia of the choroid plexus and hypoplasia of 
the cerebellar vermis.  (C) Axial T1-weighted MRI with contrast further highlights the 
diffusely enlarged choroid plexus within the lateral ventricles.  (D) Sagital T1-weighted 
MRI without contrast demonstrates the hypoplastic cerebellar vermis consistent with 
Dandy-Walker malformation.  (E) Intra-op composite endoscopic view of the right 





High-resolution array mapping of the child’s genomic DNA demonstrated 
complete tetrasomy of the short arm of chromosome 9, establishing the karyotype of the 
child as 46XX+9p.  Complete, non-mosaic tetrasomy 9p is an extremely rare, typically 
fatal syndrome with a broad range of clinical features ranging from normal phenotype to 
Dandy-Walker Malformation and perinatal demise.  This is the first description of this 
genetic anomaly using high-resolution arrays, in a viable child broadening the clinical 
spectrum to include diffuse villous hyperplasia of the choroid plexus leading to 





The child presented to neurosurgical attention at the age of three months with an 
increasing head circumference, which crossed percentiles and failure to thrive.  She was 
the product of a term pregnancy, born to healthy parents with no prior history of genetic 
disease.  On examination, the head circumference was 42.5 cm.  Sutures were splayed 
open and the anterior fontanelle was widened and tense.  The child had a unilateral (left) 
cleft lip and palate, low-set ears, micrognathia, and beaking of the nose.  Otherwise, there 
were no other noted systemic signs or symptoms.  CT/MRI demonstrated 
ventriculomegaly, hyperplasia of the choroids plexus in the lateral ventricles, and a 







The patient was taken to the operating room and a ventriculoperitoneal shunt was 
placed under endoscopic guidance.  Intra-op, marked hyperplasia of the choroid plexus 
was noted (Figure 1E).  The CSF overproduction overwhelmed her abdominal absorptive 
capacity leading to CSF ascites and wound dehiscence.  After an antibiotic course and 
shunt externalization (her CSF drainage was in excess of 1L/day), endoscopic-assisted 
surgical debulking of her bilateral choroid plexus hyperplasia was performed.  The shunt 
was then successfully internalized.  After two years of follow-up, her ventriculomegaly is 
gradually resolving as her shunt continues to function. 
 
Copy Number Variant Analysis 
 
Using the Beadstudio v3.3 genotyping software (Illumina, San Diego, CA, USA), 
analysis of the data revealed tetrasomy of the entire short arm of chromosome 9 (Figure 








Figure 7: High-resolution SNP/CNV array analysis of the patient’s genomic DNA. 
Tetrasomy of the short arm of chromosome 9: 46XX+9p (Illumina BeadStudio 








Non progressive human congenital ataxias are a rare, heterogeneous group of disorders 
that are characterized by motor disability, muscular hypotonia, incoordination, and 
impaired motor development.95-97  They present initially with general symptoms such as 
delayed motor milestones and hypotonia during the post natal period and early childhood, 
followed by the gradual onset of ataxic gait during the first few years of life. Some cases 
improve as motor functions develop, while others worsen early during infancy as motor 
demands increase on coordination. 97  
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This heterogeneous group of disorders has been associated with multiple other diseases 
including brain malformations, genetic syndromes, and congenital infections. It is 
thought that 4% of cases are due to a perinatal cause, while 45% of the cases are due to 
prenatal causes. The remaining half are speculated to be of unknown etiology.96 Of the 
associated brain malformations, cerebellar hyoplasia seems to be the most common, 
occurring in slightly less than 50% of cases. 98 The most severe cases have been noted to 
have marked hyoplasia of the vermis ,and mild to moderate involvement of the 
neocerebellum, but in other cases the neuroimaging findings have not correlated with the 
severity of the disease.98  
 
Evaluation of the distinguishable, inherited congenital ataxia syndromes with cerebellar 
hypoplasia has led to the identification of novel genes involved in the embryonic 
development of the cerebellum. Mutations in the Reelin gene have been identified to 
cause autosomal recessive lissencephaly with cerebellar hypoplasia 99, and PTF1a  
mutations have been linked to cerebellar agenesis and neonatal diabetes.100 Studies on 
Joubert syndrome, a group of recessively inherited conditions characterized by congenital 
ataxia, hypotonia, episodic breathing, mental retardation, and a specific malformation of 
the brainstem, cerebellum, and peduncles, have led to the identification of several genes 
including AHI1, NPHP1, CEP290, MKS3, and RPGR1L; encoding cilia-like functioning 
and modular scaffolding proteins.101-112 
 
Recently, mutations in the Very Low Density Lipoprotein Receptor (VLDLR) have been 
identified in patients in the Turkish 113 114, Iranian 115 and Hutterite 116 populations with 
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cerebellar atrophy and congenital ataxia following an autosomal recessive type of 
inheritance. These findings in conjunction with advances in the roles of these genes in 
mouse models have led to further understanding of the Relin-Vldlr pathway and its role 




The family originates from southeast Turkey. The two affected siblings are a product of a 
self-reported consanguineous first cousin marriage, ages 11 (NG 374-1) and 8 (NG 374-
2) at the time of presentation (Figure 8). Both patients were delivered by uneventful c-
sections with normal weights and heights at birth. They started holding their heads 
around 40 days, began to sit unsupported at age 1, and started walking at age 18 months 
with support from their hands. This is in contrast to unaffected children, which are able to 
walk unassisted on average by 15 months of age. The patients’ gait is severely ataxic, and 
they demonstrate hyperactive deep tendon reflexes. They do not exhibit any tremor. 
Examination also reveals dysarthria, dysmetria, and dysdiadokinesis, and they cannot 
construct full sentences. The older patient exhibits selective mutism, constructing full 
sentences only when speaking to himself. MRI scans from both affected siblings show 











 A. Representative pedigree of family NG-374.  Affected members are identified 
by filled symbols. Diagonal lines indicate deceased family members. Circles represent 
female and squares represent male family members.  
B. Magnetic Resonance Imaging (MRI) of the brain of affected siblings.  Sagittal 
T1 (1,2) and Coronal T2 (3,4) weighted images demonstrate prominent pachygyria and 
hypoplasia of the cerebellar vermis and hemispheres in both patients NG 374-1 (1,3) and 





Copy Number Variant Analysis 
 
 
Homozygosity mapping of the affected siblings on Beadstudio v3.3 identified a 10 kb 
homozygous block shared by both patients in chromosome 9 starting at 102,542 bps and 
ending at 10,533,899 bps.  Affected-only copy number variation analysis of both siblings 
on Human610-Quad beadchips using the PennCNV algorithm and visual inspection of 
the plotted intensities on Beadstudio v3.3 showed a shared homozygous deletion (Figure 
9) on chromosome 9 spanning approximately 9.7 kb with the first and last deleted SNP 
markers being rs2375994 and rs10967306. The deletion was noted to be within the 
previously identified homozygous block on both patients. Compared to published reports 
of genomic variation in the Database of Human Variation 
(http://projects.tcag.ca/variation/), this area does not appear to be an area of common 
variability. Homozygous deletions in the VLDLR gene were absent in 300 other Turkish 




PCR / QPCR Results 
 
PCR analysis of the patients and parents revealed a homozygous deletion in the VLDRL 
gene encompassing exon 2, exon3, and exon 4 and no comparable homozygous deletion 
in the parents (Figure 9).  Real time PCR analysis of the region confirmed the 
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homozygous deletion in both siblings, and also found a heterozygous deletion in both 
parents when compared to controls. (Figure 5) Sequence analysis revealed a 21,218 bp 
deletion including exons 2 ,3, and 4 and part of exons 1 and 5 that began on 2612144 bps 


























Figure 9:  
A. Log R ratio plot of the genome-wide SNP based genotyping demonstrates a region on 
Chromosome 9 with a microdeletion in the VLDLR gene shared by both patients.  Scatter 
points represent normalized log R ratios (y) for probe intensities along the chromosome. 
Negative values below y = -1 represent a homozygous deletion spanning 9 consecutive 
probes shared by both patients. Shaded areas represent areas of autozygosity.  
B. Closer view of the deleted region on Chromosome 9 spanning 21,218 bps 
including the 9 consecutive SNPs.  Deleted segment is represented by a black bar. 
C. Quantitative PCR results of exon 3 of the VLDLR gene within the deleted 





Inbreeding Coefficient Estimates 
 
 
Inbreeding coefficient estimates were obtained for each patient using the Inbreeding 
coefficient function of the Plink software. Because of the differences in the SNP marker 
densities, results were divided by beadchip type. The mean for the 127 patients 
genotyped on the Illumina Human CNV 370k was 0.034 with a range of -0.01 to 0.203. 
The mean for the 119 patients genotyped on the Illumina 610 Quad beadchip was 0.022 
with a range of -0.014 to 0.175. The mean for the 40 controls genotyped on the Illumina 
370k was 0.087 with a range of 0.015 to 0.22.  The overall mean for all the 245 












Table 7: Inbreeding coefficients for each subgroup.  Inbreeding coefficients were 
compared between patients that had self reported consanguinity versus patients with 
unknown or reported no consanguinity.  The mean of the inbreeding coefficients for 
patients that were reported as consanguineous was 0.075 while the mean of the patients 





Table 8: Inbreeding coefficients for patients reported as consanguineous and 
patients reported as non-consanguineous. Inbreeding coefficient mean for patients 
reported as consanguineous was significantly higher than the inbreeding coefficient for 






We are currently in the process of performing homozygosity mapping on our samples 
(results not shown) in order to find common homozygous areas that may harbor 
homozygous mutations responsible for autosomal recessive diseases in the 
consanguineous cohort. Inbreeding coefficients will be used to select a consanguineous 






The results of the two studies presented above demonstrate the utility of SNP genotyping 
and CNV analysis in uncovering the genetic basis of malformations of cortical 
development.  Specifically, two diseases are presented in this manuscript:  choroid 
hyperplasia, and cerebellar atrophy as part of the ongoing effort to identify disease-




First described in 1973117, tetrasomy 9p as a rare congenital chromosomal anomaly. Since 
that time, approximately 50 cases have been reported with a wide variety of phenotypic 
variants.  The severity of phenotype appears to correlate with the degree of mosaicism 
with non-mosaic cases resulting in perinatal demise in the first few weeks of life118-123.  
The majority of cases of 9p tetrasomy are mosaic and thus accounting for the diverse 
range of mild to severe phenotypes.  Commonality among the phenotypes has allowed for 
a syndrome to emerge consisting of hypertelorism, beaked nose, cleft palate and midface 
abnormalities, ear malformations, skeletal and joint abnormalities, hypoplasia of the nails 
and digits, hypertelorism, urogenital anomalies, developmental retardation, hypotonia, 
open sutures/wide fontanelles, clinodactyly, growth retardation, and 
ventriculomegaly/macrocephaly or microcephaly119, 120, 124, 125.   
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 Three prior infants have been described with choroid plexus pathology in 
association with 9p duplications.  Norman et al reported two patients, one with 
hemorrhagic choroid plexus hyperplasia, early perinatal demise, and mosaic tetrasomy of 
9p karyotype of 47,XY,+idic(9)(q11) and a second child developed hydrocephalus at 11 
months with choroid plexus hyperplasia on ultrasound and a trisomy 9p karyotype of 47, 
XX, +der(9)t(9;?)(q13;?)126.  The unknown, precise definition of the duplication 
demonstrates the low-resolution of Giemsa banding and traditional FISH analysis.  
Shapiro et al described a patient with bilateral choroid plexus “papillomata” and partial 
9p tetrasomy, partial 9p trisomy and a karyotype of 47, 
XX,+psudic(9)t(9;9)(9pter→9q22.1::9q12 or 13→9pter)123.  Hydrocephalus was initially 
thought to be a feature not seen in non-mosaic 9p duplications125, however,  numerous 
children are reported with mosaic and non-mosaic 9p duplications (trisomy or tetrasomy, 
complete or partial) associated with hydrocephalus119, 120, 122, 125, 127-130 or hydrocephalus 
specifically from Dandy-Walker malformations118, 131-139.  Only previously mentioned 
two papers specifically discuss the presence of choroid plexus abnormalities123, 126. 
 DVHCP is a rare disorder and results from treatment are limited to those reported 
in fewer than 10 reported cases.  Two reports have demonstrated complete resolution of 
hydrocephalus after choroid plexus resection, however there was associated morbidity 
with the approach140, 141.  The majority of cases argue for debulking of the choroid plexus 
and subsequent shunting as externalized ventricular drainage failed to demonstrate 
complete cessation of CSF overproduction90-94, 142.  This was the approach employed by 
our group. 
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The presence of 9p duplications has been examined in choroid plexus tumor 
specimens: cytogenic studies on 49 choroid plexus tumors found 9p duplication in 50% 
of choroid plexus papillomas and 33% of choroid plexus carcinomas143, while others 
have not been able to demonstrate consistent 9p duplications in choroid plexus tumors126, 
144.  The gain of 9p was associated with a significantly longer survival, and better 
prognosis for patients with choroid carcinomas143.  There likely exist genes on 9p, which 
play a role in choroid plexus growth and development.  This report expands the spectrum 
of phenotypic anomalies associated with non-mosaic tetrasomy 9p syndrome to include 
DVHCP.  As we refine the intervals on chromosome 9p involved, we will understand the 





The VLDLR gene is composed of 19 exons, spans 32 kb, and encodes a protein that is 
part of the Low Density Lipoprotein (LDL) gene family. It encodes a five domain, ligand 
binding receptor that is characterized by an N terminal 328-amino acid cysteine-rich 
ligand-binding domain, a 396-amino acid EGF precursor homology domain, a 46-amino 
acid O-linked sugar domain, a 22-amino acid single transmembrane domain, and a 54-
amino acid cytoplasmic COOH terminal domain. In humans two forms of the receptor  
have been identified, one that resembles the LDL receptor, and an alternative form with 
four domains that lacks the O-linked sugar domain. 145.The VLDLR has been suggested 
to be important in the metabolism of apoprotein-E containing triacylglycerol-rich 
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lipoproteins, beta-migrating VLDL and intermediate-density lipoproteins.146 It is also part 
of the Reelin signaling pathway 147. 
 
Reelin is an extracellular glycoprotein that is secreted by several types of neurons, 
including the Cajal-Retzius cells in the marginal zones of the cortex during embryonic 
development.148 It is important in the regulation of neuronal migration and positioning in 
the developing brain, as well as modulating synaptic plasticity and long term potentiation 
in the hippocampus during adulthood149. It has also been shown to stimulate dendrite and 
dentritic spine development 150, and the continual migration of neuroblasts generated in 
adult neurogenesis sites such as the subventricular zone and dentate nucleus.151 It is 
thought to interact through one of two receptors, the VLDLR and the Apolipoprotein-E 
Receptor Type 2 (ApoER2)152, on several intracellular proteins including Dab-1, an 
adapter protein. 147 According to a recent study, these two receptors might have divergent 
roles with VLDLR conducting the stop signal for migrating neurons while ApoER2 is 
essential for the migration of late-born neocortical neurons.153 
 
Reelin -/- mice were originally described by Falconer et. al in 1951 and were named for 
their distinct ataxic and “reeling” gait.154 Affected mice exhibit failed migration of the 
Purkinje cells, inverted cortical lamination, cerebellar hypoplasia, and ataxia.155-158. In 
humans, homozygous mutations of the Reelin gene are responsible for a type of 
autosomal recessive lissencephally, Norman-Roberts syndrome99. Another protein found 
to have a role in lissencephally, Pafahb1 (LIS1), was also shown to be part of the reelin 
pathway, interacting with the intracellular segment of VLDLR.159  
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Mutations in the VLDRL gene have been previously described both in humans and in 
animal models. Vldlr -/- mice appear to be grossly and neurologically normal, but contain 
ectopically located Purkinje cells in the cerebellum and radially aligned neurons in the 
cortex that appear to have failed to distribute152, 160. The first mutation observed in a 
human case in the gene was in the Hutterite population116 where a 199-kb homozygous 
deletion encompassing the complete VLDLR gene and possibly adjacent regulatory 
regions was noted to be responsible for the “Dysequillibrium Syndrome”. Originally 
described in the 1980s, the “Dysequillibrium Syndrome” in the Hutterite population 
consisted of an autosomal recessive constellation of non-progressive cerebellar ataxia, 
mental retardation, and cerebellar hypoplasia161, 162.  Patients were also noted to have 
delayed ambulation, strabismus, mild cortical simplification on MRI, and short stature 
(15%).  However, this deletion also encompassed adjacent regulatory regions, and 
possibly a second gene.  It was therefore unclear whether a mutation in VLDRL could 
solely explain the syndrome in its entirety.  Subsequently, a homozygous nucleotide 
substitution in exon 10 resulting in a premature stop codon in the VLDLR gene identified 
in an Iranian family with Disequilibrium Syndrome gave rest to this argument, and 
indeed showed that a truncated VLDRL protein in isolation was a satisfactory cause of 
DES.   
 
Since then, three Turkish families have been reported with Unertan Syndrome, which is a 
rare autosomal recessive neurodevelopmental condition with cerebellar and cortical 
hypoplasia accompanied by mental retardation, primitive and dysarthric speech, and most 
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notably, quadrupedal locomotion163.  One non-sense and one frameshift mutation (in two 
separate families) resulting in premature stop codons in exons 5 and 17 were identified in 
the Turkish families with Unertan syndrome, presumably causing the VLDLR to lack 
transmembrane and signaling domains.  
   
The cause of differences in locomotion phenotype are unclear, but Ozcelik et al. argue 
that it might be a result of different mutations in the same gene leading to different 
phenotypes, and variable expressions of the disease phenotype.114, 164 Ozcelik et al 
explain that they believe quadrupedal gait to be the result of their reported homozygous 
deletions resulting in this specific gait compared to the mutations resulting in the 
Dysequillibrium syndrome. In contrast, Herz and Humphrey argue that quadrupedal 
locomotion has developed in a subset of reported patients with VLDLR deletions as an 
adaptive process to the severe truncal ataxia, and the Unertan syndrome does not 
represent a separate genetic entity165, 166.  They believe that rural surfaces, imitation of the 
behavior of other affected siblings, lack of medical attention, and social acceptance of 
quadrupedal gait without correction are believed to have contributed to the development 
of quadrupedal gait in these patients. Even though it is true that some families were 
isolated from medical attention, this claim has also been debated by the presence of 
families where extensive medical care was sought, and quadrupedal gait was strongly 
discouraged yet still developed.  
 
Including our recent report, to date five different mutations in nine families have been 
described in the VLDLR gene including the original description in the Hutterites.  
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Structural examination of the gene and the defective protein does not reveal any 
identifiable portion that seems to be responsible for quadrupedal gait.  A stop codon in 
exon 5 and a frameshift mutation in exon 17 both lead to quadrupedal gait in Turkish 
families, whereas a stop codon in exon 10, and our recent report of a deletion affecting 
exons 1-5 resulted in bipedal, ataxic gait.  Thus, it is likely that DES and Unertan 
syndrome are clinically, but not genetically distinct syndromes, and represent a spectrum 
of disease resulting from dysfunctional VLDLR protein.  Where along the spectrum an 
affected patient will lay is likely the product of a complex interaction between genetic 
makeup and the environment, and cannot be predicted based on the mutation alone.  It is 
unlikely that VLDRL represents an indispensable gene in human bipedalism and 
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